2seventy Bio, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Bristol-Myers Squibb finalizes its acquisition of 2seventy bio for $5.00 per share, totaling approximately $264.6 million, leading to delisting from NASDAQ and significant management changes.
2seventy bio announced its first quarter 2025 financial results, highlighting Abecma's U.S. commercial performance and progress toward acquisition by Bristol Myers Squibb (BMS), expected to close in the second quarter of 2025.
2seventy bio announces a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS) for $5.00 per share in cash, alongside reporting its Q4 and full year 2024 financial results, highlighting a focus on Abecma commercialization and cost structure streamlining.
Bristol Myers Squibb will acquire 2seventy bio in an all-cash transaction for $5.00 per share, valuing the company at approximately $286 million.
2seventy bio announces preliminary U.S. Abecma sales of $242 million for 2024 and targets quarterly breakeven by the end of 2025.
2seventy bio, Inc. announced the appointment of Jessica Snow as its new Chief Operating Officer, effective January 6, 2025.
2seventy bio announced a 42% increase in Abecma sales compared to the previous quarter, alongside significant cost reductions and a net loss of approximately $10 million for the third quarter of 2024.
2seventy bio reported approximately $77 million in U.S. revenue for Abecma in the third quarter of 2024, based on information from Bristol Myers Squibb.
8-K: 2seventy bio Halts Enrollment in KarMMa-9 Study, Anticipates Strong Q3 Revenue Growth for Abecma
2seventy bio discontinues enrollment in the Phase 3 KarMMa-9 study, expecting over $80 million in cost savings and a 30% revenue increase for Abecma in Q3.
2seventy bio announced its second quarter financial results, showcasing a significant reduction in operating expenses and a focus on Abecma commercialization following strategic asset sales.
2seventy bio reported approximately $54 million in U.S. revenue for Abecma in the second quarter of 2024, based on information from Bristol Myers Squibb.
2seventy bio has sold its Hemophilia A program and related gene editing technology to Novo Nordisk for up to $40 million, allowing the company to focus on its Abecma cancer therapy.
2seventy bio held its 2024 Annual Meeting of Stockholders, electing three Class III directors and ratifying Ernst & Young LLP as its independent auditor.
2seventy bio announced its first quarter 2024 financial results, highlighting the FDA approval of Abecma for earlier lines of multiple myeloma treatment and a strategic realignment focusing on Abecma's commercialization.
2seventy bio reported approximately $52 million in U.S. revenue for Abecma in the first quarter of 2024, based on information from Bristol Myers Squibb.
2seventy bio announced FDA approval for a new manufacturing process for Abecma and the withdrawal of Engine Capital's board nominees.
The FDA has approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, expanding its availability to more patients.
2seventy bio has finalized the sale of its oncology and autoimmune pipeline to Regeneron, and will now concentrate on the development and commercialization of Abecma.
8-K: 2seventy bio Completes Sale of Oncology and Autoimmune Pipeline to Regeneron, Shifts Focus to Abecma
2seventy bio has finalized the sale of its oncology and autoimmune programs to Regeneron for $5 million upfront, shifting its focus to the commercialization of Abecma.
2seventy bio has appointed Eli Casdin and Charles Newton to its Board of Directors, while also acknowledging a nomination of two additional candidates by Engine Capital for the upcoming annual meeting.
2seventy bio reports a positive FDA advisory committee vote for Abecma and an agreement regarding the departure of their chief scientific officer.
2seventy bio has extended the deadline for director nominations for its 2024 annual meeting to March 22, 2024.
2seventy bio reported its Q4 and full year 2023 financial results, highlighted by a strategic realignment focusing on Abecma and an upcoming FDA review for label expansion.
2seventy bio reported $56 million in U.S. revenue for Abecma in Q4 2023 and announced an upcoming FDA advisory committee meeting to review its expanded use.
2seventy bio has appointed William D. Baird, III as CEO and Victoria Eatwell as CFO, effective January 29, 2024, with both receiving new employment agreements.
2seventy bio will sell its oncology and autoimmune research programs to Regeneron and focus on the commercialization of Abecma, resulting in significant cost savings and a leadership transition.